Zoetis Inc. $ZTS Shares Sold by Van Lanschot Kempen Investment Management N.V.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Van Lanschot Kempen Investment Management N.V. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 19.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 137,539 shares of the company's stock after selling 32,400 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in Zoetis were worth $22,646,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Portside Wealth Group LLC increased its holdings in shares of Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. boosted its holdings in Zoetis by 100.3% in the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC increased its stake in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after purchasing an additional 1,760 shares during the last quarter. Horizon Financial Services LLC acquired a new stake in shares of Zoetis during the first quarter worth $380,000. Finally, Sage Rhino Capital LLC raised its holdings in shares of Zoetis by 117.6% during the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after purchasing an additional 3,791 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Stock Performance

Zoetis stock traded down $1.2650 during mid-day trading on Thursday, hitting $155.4950. 2,411,616 shares of the company's stock traded hands, compared to its average volume of 3,540,633. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The firm has a 50 day moving average price of $154.00 and a 200 day moving average price of $158.75. The company has a market cap of $68.91 billion, a PE ratio of 26.76, a price-to-earnings-growth ratio of 2.52 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company earned $1.56 earnings per share. The company's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.18% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.